Search Results for: initial regimen

General Considerations with Initial ART Regimens

Medical Care Criteria Committee, April 2017 The recommended antiretroviral therapy (ART) regimens should work well for the majority of properly selected patients, but some circumstances may make one regimen more favorable than another for a given individual. In general, an integrase strand transfer inhibitor (INSTI)-based regimen will be the best option for most patients [Lee … Continue reading “General Considerations with Initial ART Regimens”

General Principles in Choosing an Initial ART Regimen

Medical Care Criteria Committee, June 2018 Goals of ART: The issue of when to start ART was settled with the publication of the START (Strategic Timing of Antiretroviral Treatment) and TEMPRANO (Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults) studies early in 2015 [INSIGHT START 2015; TEMPRANO ANRS 12136 2015]. Treatment is … Continue reading “General Principles in Choosing an Initial ART Regimen”

Available ART Regimens

Medical Care Criteria Committee, updated June 2018                                             Note: The recommendations in this guideline pertain to initial antiretroviral therapy (ART) regimens for adults with HIV infection who are not pregnant. RECOMMENDATIONS Available Antiretroviral Agents and … Continue reading “Available ART Regimens”

ART Regimens for oPEP

Medical Care Criteria Committee, updated May 2018 RECOMMENDATIONS Table 1: Recommended Preferred and Alternative Antiretroviral Regimens for oPEP Preferred oPEP Regimen Note: All are oral medications Notes Tenofovir disoproxil fumarate (TDF) 300 mg daily plus emtricitabine (FTC) 200 mg daily plus raltegravir (RAL) 400 mg twice daily or dolutegravir (DTV) 50 mg daily [see DTG safety statement, … Continue reading “ART Regimens for oPEP”

ART Regimens for nPEP

Medical Care Criteria Committee, updated May 2018 RECOMMENDATIONS Post-Exposure Prophylaxis Regimens for Non-Occupational Exposures to HIV  Table 1: Preferred and Alternative Antiretroviral Regimens for nPEP RECOMMENDED Regimen Note: All are oral medications Notes Tenofovir disoproxil fumarate (TDF) 300 mg* daily plus emtricitabine (FTC) 200 mg daily plus raltegravir (RAL) 400 mg twice daily or dolutegravir (DTV) … Continue reading “ART Regimens for nPEP”

Initial Assessment

Medical Care Criteria Committee, October 2014 RECOMMENDATIONS This section provides guidance for assessing non-occupational exposures that occur from blood and body fluid exposures, including sexual and needle-sharing activities unrelated to sexual assault. (Special considerations for PEP following sexual assault are covered in PEP for Victims of Sexual Assault). Situations that may prompt a request for nPEP include … Continue reading “Initial Assessment”

Updates to this Guideline

June 2018 Available Antiretroviral Agents: Single-Tablet Regimens versus Multi-Tablet Regimens Bictegravir (BIC; Biktarvy) added as a preferred initial ART regimen for patients with CrCl >30 mL/min, with related updates throughout all sections of the guideline. New footnote (6) added to all regimen tables: “When a ‘rapid start’ or ‘test and treat’ initiation of ART occurs … Continue reading “Updates to this Guideline”

Specific Factors to Consider and Discuss with Patients

Medical Care Criteria Committee, June 2018 Before initiating antiretroviral therapy (ART), the following factors are important to consider and discuss with patients. Age: As individuals with HIV age, they have a higher prevalence of comorbidities than younger patients and are likely to be on more non-HIV-specific medications, particularly cardiovascular or gastrointestinal agents, posing a higher risk … Continue reading “Specific Factors to Consider and Discuss with Patients”